Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Akebia Therapeutics ( (AKBA) ).
Akebia Therapeutics has entered a multi-year commercial supply agreement with a leading dialysis organization to provide access to its drug Vafseo® (vadadustat) for dialysis patients. This strategic move could enhance Akebia’s market presence in the dialysis segment, offering potential growth opportunities.
Learn more about AKBA stock on TipRanks’ Stock Analysis page.
